The "Global Immunology Market 2018-2022" report has been added to ResearchAndMarkets.com's offering.

The global immunology market will grow at a CAGR of 4.57% during the period 2018-2022.

The Global Immunology Market 2018-2022, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

The latest trend gaining momentum in the market is significant pipelines; there are multiple promising immunological agents in the pipeline, which boost market growth after approval. The approval of new therapeutic agents broadens the options available for treatment and thus leads to the increase in demand for the therapeutic regimen.

There are approximately 51 molecules under different clinical trial stages globally. Of them, 22 molecules are in Phase II, four molecules are in Phase III, 16 molecules are in Phase I, and the remaining are in Phase I.

One of the most promising molecules under development from AbbVie is risankizumab (ABBY-066).

Boehringer Ingelheim and AbbVie are jointly working on the molecule to get approval for new indications such as psoriasis, psoriatic arthritis, and Crohn's disease. This combination is currently going through Phase III clinical trial for psoriasis and Phase II for psoriatic arthritis and Crohn's disease.

Key vendors

  • AbbVie
  • Amgen
  • F. Hoffmann-La Roche
  • Johnson & Johnson

Other prominent vendors

  • Angimmune
  • Bionor Pharma
  • Boston Biomedical
  • Celgene
  • Cellectar Biosciences
  • eFFECTOR Therapeutics
  • Forty Seven
  • HANSOH
  • Immatics Biatechnologies
  • lmmunovaccine
  • Karyopharm Therapeutics
  • MabVax Therapeutics
  • MedImmune
  • MOLOGEN
  • Neon Therapeutics
  • NewLink Genetics
  • Novartis
  • ONCOQUEST
  • Oncotherapeutics.

Key Topics Covered:

Part 01: Executive Summary

Part 02: Scope Of The Report

Part 03: Research Methodology

Part 04: Introduction

Part 05: Market Landscape

Part 06: Market Sizing

Part 07: Five Forces Analysis

Part 08: Pipeline Landscape

Part 09: Market Segmentation By Category

Part 10: Market Segmentation By Indication

Part 11: Customer Landscape

Part 12: Regional Landscape

Part 13: Decision Framework

Part 14: Drivers And Challenges

Part 15: Market Trends

Part 16: Vendor Landscape

Part 17: Vendor Analysis

Part 18: Appendix

For more information about this report visit https://www.researchandmarkets.com/research/g8mxdx/global_immunology?w=4